hotspot -WSS

hotspot

author：comprehensive 2025-09-04 02:35:02 - browse：97

LONDON — In a bid to expand its pipeline of inflammation-targeting drugs, Sanofi said Tuesday it was acquiring California-based Inhibrx in a deal worth up to $2.2 billion.

The core of the deal is Inhibrx’s experimental therapy for AATD, a disease that progressively damages the lungs and liver. The medicine, INBRX-101, is designed to reduce inflammation and stave off further damage to the tissue. Inhibrx has completed Phase 1 testing of the drug and is enrolling patients in a Phase 2 trial.

Inhibrx’s other drug candidates, including its line of cancer-targeting immunotherapies, will be portioned out into a new company that will continue to be called Inhibrx. Mark Lappe, the founder and CEO of Inhibrx, will lead the spun-out company.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： What affirmative action's end means to a medical student

WSS

Skip the lead apron during X

Grandmother of French teen shot dead by police officer pleads with rioters to stop the violence

FDA advisers back CAR

Readout Newsletter: Bristol, Sangamo, Gilead, and more

The wait for US passports is creating travel purgatory and snarling summer plans

'Screen and refer' systems are hurting patients

leisure time

hotspot

knowledge

Novavax promises a turnaround & Lilly roils the obesity market

Pushing for an NIH office for post

23andMe had bad news about my health. I wish a person had delivered it

UCLA team creates talking throat patch for voice disorders

Drug repurposing or repositioning? The language matters

Dexcom's push to bring CGM to type 2 diabetes patients

Alkermes shareholders re

Undocumented workers face uncertainty as immigration law takes effect in Florida

Moonlake's readout produced a cash windfall. Risks remain

How to save health care price transparency rules

knowledge

President Biden's budget: Here's what you might have missed

Steward Health Care Massachusetts hospitals face fiscal disaster

The wait for US passports is creating travel purgatory and snarling summer plans

UCLA team creates talking throat patch for voice disorders

UCLA team creates talking throat patch for voice disorders

Top Ukrainian generals say counteroffensive is 'going to plan' as losses mount

focus

leisure time

entertainment

hotspot